Sanbo Brain, a well-known neurosurgery hospital group, recently announced the completion of a Series B equity financing of over 800 million yuan. This round of financing was led by Taikang, with participation from Park Road Capital, GF Xinde and other institutions. financial consultant.

Sanbo Brain was founded in 2004. After 16 years of development, it has become a well-known neurological specialist chain medical group in China. It has 7 large hospitals (including 1 under construction), covering Beijing, Chongqing, Hunan, Fujian, Henan, In 6 provinces and cities including Yunnan, the flagship hospital, Sanbo Brain Hospital of Capital Medical University, is one of the top neurological specialist hospitals in China. Xuanwu Hospital ranks at the forefront of neurosurgery together. Since the establishment of the hospital, Sanbo Neurology has always adhered to the development path of "integration of medicine, teaching and research", with neuromedical experts Luan Guoming, Yu Chunjiang, Shi Xiangen, Wang Baoguo, Yan Changxiang, Wu Bin, Lin Zhixiong, Fan Tao, etc. A large number of medical elites with profound medical knowledge, rich clinical experience and modern medical concepts have laid a solid foundation for developing high-quality medical services, improving a systematic talent training mechanism, and improving discipline construction and scientific research.

Speaking of this financing, Zhang Yang, Chairman of Sanbo Brain Group, said: "Thank you Taikang Insurance Group, GF Xinde and other investment institutions for their recognition of Sanbo Brain. For the existing high technical barriers like Sanbo Brain, The socially-run medical institutions operated in a group chain are inseparable from the help and support of social capital in the process of development. With the help of Yikai Capital, the successful completion of this financing fully demonstrates the capital market's commitment to Sanbo's brand and value. It is recognized that this will effectively promote the sustainable development of Sanbo. In the future, Sanbo will increase investment in scientific research transformation, talent reserve, medical hardware, etc., consolidate the brand, promote the regional network layout in an orderly manner, and achieve large-scale and rapid growth. Help more patients regain their health."

As the lead investor of this round of financing, Xu Jun, head of the strategic equity investment department of Taikang Assets, said: "The neurology specialist market is large in scale and has high technical barriers. Through nearly 20 years of solid accumulation, the team of Sanbo has achieved great success in technology. , brand, talent echelon, scale, etc. has grown into a leader in private neurology. Taikang is very happy to be the lead investor in this round and join hands with other shareholders to help Sanbo further develop and grow. In the future, Taikang will also actively cooperate with Sanbo. Explore cooperation in health insurance, health management, etc., to bring better service experience to insurance customers."

Lu Yancen, founding partner of Park Road Capital, said, "Sanbo Neurology is China's top private intensive care specialist hospital; it is also a first-line brand of neurology. There is a huge demand for neurological diseases brought about by the aging society in China and around the world. Based on the top neuromedical experts in China, combined with an efficient operation management system, it has achieved rapid growth in discipline construction, operation management, and hospital construction. Park Dao Medical is honored to be a shareholder of Sanbo Brain, and takes this opportunity as an opportunity , to promote long-term strategic cooperation, assist the future development of Sanbo Brain, and contribute to medical technology, capital market, operation management, etc. This investment in Sanbo Brain will further enrich the Pudao medical ecosystem.”